Chapter 34.Cariprazine
Sections
Excerpt
Cariprazine (Vraylar) was initially discovered by the Hungarian company Gedeon Richter Ltd. (November 2004) and was developed by Forest Laboratories and submitted to the U.S. Food and Drug Administration (FDA) in November 2012 (Forest Laboratories 2012). In September 2015, cariprazine was approved by the FDA for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder in adults (Actavis Inc. 2015) (Figure 34–1). Cariprazine is also in development in a variety of countries for use in the treatment of schizophrenia with predominantly negative symptoms (Phase III), for use as an adjunct in the treatment of major depressive disorder (Phase II/III), and for use in the treatment of bipolar depression (Phase II) (McCormack 2015).
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
